A detailed history of National Bank Of Canada transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, National Bank Of Canada holds 2,936 shares of TRVI stock, worth $33,264. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,936
Previous 2,501 17.39%
Holding current value
$33,264
Previous $13,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$5.62 - $9.62 $2,444 - $4,184
435 Added 17.39%
2,936 $26,000
Q2 2025

Aug 13, 2025

BUY
$5.28 - $7.06 $13,205 - $17,657
2,501 New
2,501 $13,000

Others Institutions Holding TRVI

About Trevi Therapeutics, Inc.


  • Ticker TRVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,322,500
  • Market Cap $661M
  • Description
  • Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...
More about TRVI
Track This Portfolio

Track National Bank Of Canada Portfolio

Follow National Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of National Bank Of Canada , based on Form 13F filings with the SEC.

News

Stay updated on National Bank Of Canada with notifications on news.